A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Bb 2121 (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms KarMMa
- Sponsors Celgene Corporation
- 21 Feb 2018 According to the bluebird bio media release, first patient was infused in this study.
- 08 Jan 2018 According to a Celgene Corporation media release, the company expects to complete enrollment in the trial in 2018.
- 07 Dec 2017 New trial record